# Graviton BioScience Announces FDA Fast Track Designation for GV101 for the Treatment of Friedreich's Ataxia

- Source: PR Newswire M&A
- Published: 2026-11-03T13:30:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/graviton-bioscience-announces-fda-fast-track-designation-for-gv101-for-the-treatment-of-friedreichs-ataxia-302926880.html
- Canonical: https://groundlevelnews.com/story/graviton-bioscience-announces-fda-fast-track-designation-for-gv101-for-f56f65/

Fast Track Designation recognizes the serious unmet medical need in Friedreich's ataxia and is intended to facilitate the development and expedite the review of GV101. GV101 is a potent, highly selective oral ROCK2 inhibitor that has demonstrated the ability to increase frataxin protein...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._